Historic Market Decline
South Korea’s stock market has experienced its steepest fall in history, with the KOSPI index plummeting by 12.06 percent on March 4, 2026. This unprecedented drop comes in the wake of escalating tensions due to the ongoing US-Iran war, which has significantly affected global markets and investor confidence.
Record-Breaking Losses
The KOSPI’s decline surpassed the previous record of 12.02 percent set after the September 11, 2001 attacks. The situation prompted South Korean financial authorities to activate a 20-minute circuit breaker after losses exceeded the 8 percent threshold. This measure aims to prevent further panic selling and stabilize the market.
Impact on Key Industries
In addition to the stock market’s downturn, shipping and logistics firms have suffered the steepest losses. The effective halt of traffic through the Strait of Hormuz, a critical passage for oil shipments, has disrupted supply chains and raised concerns about energy security in South Korea, which relies on foreign oil for about 98 percent of its fossil fuel needs.
Recent Market Trends
Prior to this historic plunge, the KOSPI had already fallen by 7.2 percent on March 3, 2026, marking the worst two-day streak in decades. Major corporations such as Samsung Electronics, SK Hynix, and LG Electronics have seen their stock prices decline sharply, reflecting the broader economic impact of the geopolitical crisis.
Healthcare Sector Developments
Despite the turmoil in the stock market, there are positive developments in South Korea’s healthcare sector. Roche Holding AG has announced plans to invest approximately 710 billion won (around $481 million) in the country’s healthcare and biotechnology sector over the next five years. This investment includes conducting global clinical trials for treatments targeting prevalent and hard-to-treat diseases.
Clinical Trials and Research Growth
The partnership between Roche and South Korean institutions aims to elevate the country’s clinical trial capabilities, with the goal of helping local biohealth companies grow faster and expand into global markets. Clinical trials in South Korea are estimated to be about 30-40 percent cheaper than in the US or Japan, making the country an attractive destination for pharmaceutical research.
Global pharmaceutical companies invested around 1.04 trillion won in Korean clinical research in 2024, reflecting a 74 percent increase from 2020. Seoul had ranked first globally for clinical trial activity for seven consecutive years starting in 2017, although it slipped to second place in 2024. The future of South Korea’s stock market and economy remains uncertain as geopolitical tensions continue to evolve, and details remain unconfirmed.
